Undisclosed BID Degraders
Rheumatoid Arthritis; Inflammatory Bowel Disease
DiscoveryActive
Key Facts
Indication
Rheumatoid Arthritis; Inflammatory Bowel Disease
Phase
Discovery
Status
Active
Company
About Captor Therapeutics
Captor Therapeutics leverages its proprietary Optigrade™ platform to discover and develop novel therapeutics based on Targeted Protein Degradation (TPD), a revolutionary approach to address high unmet medical needs. The company, with R&D labs in Wroclaw, Poland, and business operations in Basel, Switzerland, has secured over €76 million in non-dilutive grant funding for its R&D projects. Its pipeline includes a first-in-class MCL-1 degrader for resistant cancers and programs in colorectal cancer and autoimmune diseases, positioning it as a key European player in the competitive TPD field.
View full company profile